DISTRICT OF COLUMBIA: It’s a perfect storm situation for AXIM Biotechnologies. July 9, The FDA announced serious warnings for NSAIDs anti-inflammatory drugs- drugs which AXIM say their medicated gum can replace. AXIM recently acquired intellectual rights for a U.S. patent for time-release cannabidiol chewing gum. CanChew Biotechnologies will hold the patent for production with a 50 year licensing agreement with AXIM. AXIM is strategically entering the market at the right time.
AXIM’s new focus is to introduce proprietary delivery mechanisms for the introduction of cannabinoids. The company is known for green alternative hemp energy among other innovations and has been developing their patent-pending cannabinoid delivery system at the Free University of Amsterdam.
AXIM claims to have found a way to bypass first-pass liver metabolism and the insolubility of cannabinoids. Dr. George E. Anastossov, CEO of AXIM Biotechnologies, told Yahoo Finance,“AXIM’s business focus has been and continues to be on being an innovative biotechnology company working on solutions for the treatment of pain, spasticity, anxiety and other medical disorders and symptoms with the application of cannabinoid-based products as well as focusing on research, development and production of pharmaceutical, nutraceutical, oral health and cosmetic products as well as procurement of genetically and nano-controlled active ingredients.”